Literature DB >> 16755770

[Buerger's disease].

M Chochola1, K Márová, A Linhart.   

Abstract

Buerger's disease (Thromboangiitis obliterans--TAO) is a nonatherosclerotic, segmental inflammatory disease that most frequently affects the small and medium-sized arteries and veins in the upper and lower extremities. There exists an extremely strong association between heavy tobacco use and TAO. The histopathology of the involved blood vessels varies according to the chronologic stage of the disease at which the tissue sample is obtained for examination. The histopathology is most likely to be diagnostic at the acute phase of the disease. Buerger's disease typically occurs in young male smokers, with the onset of symptoms before the age of 40 to 45 years. Several published series have shown an increasing prevalence of the disease in women. There is little information on the use of intra-arterial thrombolytic therapy, prostaglandin therapy, or angiogenesis. Discontinuation of tobacco use is the mainstay of treatment. Patients who successfully stop smoking almost never need amputation.

Entities:  

Mesh:

Year:  2006        PMID: 16755770

Source DB:  PubMed          Journal:  Cas Lek Cesk        ISSN: 0008-7335


  4 in total

1.  Thromboangitis Obliterans involving Bilateral Upper limb Extremities - A Rare Case Report from Malaysia.

Authors:  Uthamalingam Murali; Mohammad Azhar Anis Ahmad; Fatin Najihah
Journal:  J Clin Diagn Res       Date:  2017-03-01

2.  Etiopathogenesis, clinical diagnosis and treatment of thromboangiitis obliterans - current practices.

Authors:  Edwaldo Edner Joviliano; Renata Dellalibera-Joviliano; Marcelo Dalio; Paulo Rb Evora; Carlos E Piccinato
Journal:  Int J Angiol       Date:  2009

3.  A Rare Case of Thromboangiitis Obliterans of Bilateral Upper Extremities in an Adult Male.

Authors:  Toluwalope F Ejiyooye; Abimbola O Ajibowo; Sudha Dirisanala; Bukola Olagbende; Uchenna E Ezenagu; Aadil Khan
Journal:  Cureus       Date:  2022-05-13

4.  Activation of cytokines corroborate with development of inflammation and autoimmunity in thromboangiitis obliterans patients.

Authors:  R Dellalibera-Joviliano; E E Joviliano; J S Silva; P R B Evora
Journal:  Clin Exp Immunol       Date:  2012-10       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.